Expert Ratings for Immuneering
Portfolio Pulse from Benzinga Insights
Immuneering (NASDAQ:IMRX) has received 3 bullish, 1 somewhat bullish, and 2 indifferent analyst ratings in the last quarter. The average 12-month price target for the stock is $18.83, up 47.69% from the previous average of $12.75.
June 26, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immuneering has received positive analyst ratings in the last quarter, with an average 12-month price target of $18.83, up 47.69% from the previous average.
The positive analyst ratings and the significant increase in the average 12-month price target suggest that analysts are optimistic about Immuneering's stock performance in the short term. This could lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100